SCHEMBL29303098

SCHEMBL29303098

Brc1ncccc1OCc1cn2cc(C3CC3)ccc2n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 9/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ METTL3 Q86U44 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.35
▸ DRD4 P21917 2/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ PIM2 Q9P1W9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24729661 0.77 SMN1; SMN2 (0.46) KLKB1KDM4ENPC1RAB9ALMNA
SCHEMBL24729570 0.77 SMN1; SMN2 (0.41) KLKB1KDM4ENPC1RAB9ALMNA
SCHEMBL29958329 0.77 SMN1; SMN2 (0.42) KLKB1KDM4ENPC1RAB9ALMNA
SCHEMBL30997865 0.74 KLKB1 (0.39) KLKB1METTL3
SCHEMBL29957835 0.74 METTL3 (0.38) KLKB1METTL3
SCHEMBL29303099 0.74 KLKB1 (0.39) KLKB1METTL3
SCHEMBL24739315 0.74 KLKB1 (0.39) KLKB1KDM4EMAPTNPC1RAB9A
SCHEMBL29880148 0.74 KLKB1 (0.39) KLKB1KDM4EMAPTNPC1RAB9A
SCHEMBL21354799 0.73 METTL3 (0.45) KLKB1METTL3
SCHEMBL24729569 0.73 METTL3 (0.39) KLKB1KDM4ENPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 KLKB1 1/4885KDM4E 796/4885MAPT 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback